Pfizer signs exclusive licensing deal with Starna for in‑vivo CAR‑T programs

Pfizer entered an exclusive agreement with China‑based Starna Therapeutics to obtain worldwide rights, except Greater China, to three pre‑IND in‑vivo CAR‑T programs targeting autoimmune diseases. The deal includes a US$330 million upfront payment and up to US$2.3 billion in development and commercial milestones, for a total potential value of about US$2.6 billion. Pfizer will lead clinical development, manufacture initial clinical supplies in the United States and retain full commercialization control outside Greater China, while Starna keeps rights in Greater China.

The upfront cash outflow of US$330 million reduces Pfizer’s short‑term liquidity, while the large milestone upside could affect future cash flows if the programs advance. The agreement expands Pfizer’s pipeline into in‑vivo cell therapy, a strategic area as the company seeks growth beyond its COVID‑19 products.

  • 1Pfizer will pay Starna an upfront amount of US$330 million.
  • 2Starna can earn up to US$2.3 billion in milestone payments tied to development and commercial milestones.
  • 3The total potential value of the deal is about US$2.6 billion.
  • 4Pfizer receives exclusive rights outside Greater China to develop, manufacture and commercialize three pre‑IND in‑vivo CAR‑T programs for autoimmune diseases.
  • 5Starna retains rights to the programs in Greater China.
  • 6Pfizer will lead clinical development and manufacture the initial clinical drug product in the United States.

Sources